If Namenda is not helping, the next step is a clinical reassessment—not automatically a stronger dementia drug. The clinician should verify the diagnosis and stage, review the dose and side effects, and look for other causes of decline. Namenda, the brand name for memantine, treats symptoms rather than the disease itself. The FDA-approved indication is moderate-to-severe dementia of the Alzheimer's type, so its apparent failure does not establish that it has failed for every dementia diagnosis.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does "not helping" actually mean?
- What should the reassessment check?
- Which treatment options might change?
- Are newer anti-amyloid treatments the next step?
- How should behavior and caregiving needs be handled?
What does "not helping" actually mean?
Memantine does not stop or reverse Alzheimer's disease. According to the National Institute on Aging, it may help some people maintain daily functions longer. That makes benefit hard to judge from memory alone.
A person may keep declining even if the drug temporarily supports dressing, conversation, or other daily activities. Ask the prescriber to define the treatment target and compare it with a recorded baseline. Useful questions include whether function, behavior, confusion, or caregiving demands changed after treatment began.
What should the reassessment check?
A new or accelerating decline should not automatically be labeled dementia progression. The National Institute on Aging identifies possible contributors such as medication effects, illness-related delirium, depression, vitamin deficiencies, metabolic or endocrine problems, stroke, tumors, and other dementias. Some causes may improve with treatment.
A medication review is also essential. Namenda's common adverse reactions include dizziness, headache, confusion, and constipation—problems that can obscure whether treatment is helping. The clinician should review:.
- The exact dose, schedule, and missed doses
- When the decline or new symptoms began
- Prescription and nonprescription medicines
- Dizziness, headaches, constipation, or increased confusion
- Kidney function, since severe renal impairment requires a lower target dose of 5 mg twice daily
Which treatment options might change?
For moderate-to-severe Alzheimer's, a clinician may combine memantine with a cholinesterase inhibitor because the drug classes work differently. Approved options at this stage include donepezil, the rivastigmine patch, and a memantine-donepezil combination.
The practical choices are not limited to "continue" or "stop." A prescriber might correct the dose, address adverse effects, add or change a symptom medicine, or conclude that its limited benefit no longer supports continued use. No alternative guarantees visible improvement. The decision should reflect the confirmed diagnosis, disease stage, previous treatments, tolerability, daily function, and the family's care goals.
Are newer anti-amyloid treatments the next step?
Not usually for someone who already has moderate-to-severe dementia. Anti-amyloid medicines target an earlier phase of Alzheimer's disease and should not be treated as replacements for ineffective Namenda at a later stage. For example, the FDA label for Leqembi says treatment is initiated only in people with confirmed amyloid and either mild cognitive impairment or mild Alzheimer's dementia.
It also requires an MRI before treatment and repeated MRI monitoring. These treatments aim to slow measured decline; they do not restore lost cognition. Eligibility, stage, monitoring demands, and serious risks must be reviewed before considering them.
How should behavior and caregiving needs be handled?
For agitation or other behavioral symptoms, comfort and environmental approaches come first. Caregivers can simplify routines, reduce avoidable noise, and note when distress appears alongside discomfort or a particular situation.
Antidepressants, antipsychotics, or anti-anxiety medicines may help selected people, but a clinician must weigh their potential benefits and risks. Follow-up should also address changing safety needs and caregiver strain, not just test scores. Before the next appointment, prepare:.
- A dated list of cognitive, behavioral, and functional changes
- The complete medication list with doses
- Specific examples of lost abilities or possible side effects
- Current safety concerns and caregiver limits
- A request for a documented plan to continue, adjust, combine, or discontinue treatment under clinical supervision, plus a date to review the result
